ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 21 of 45
JMBS 2018, 3(3): 113–118
Clinical Medicine

Therapy Effect on the Levels of Inflammation Biomarkers P-Selectin and Galectin-3 in Patients with Stable Angina Pectoris and Type 2 Diabetes Mellitus

Khvysiuk M. A., Bilchenko A. V., Rudenko T. A.

The study of standard and specific therapy effects on patients with angina and type 2 diabetes can provide a rationale for the individualization of therapy aimed at reducing the "residual" cardiovascular risk associated with systemic inflammation. The purpose of the study was to analyze changes in the levels of new biomarkers of P-Selectin and Galectin-3 inflammation in patients with stable angina depending on the therapy. Materials and methods. 89 patients with angina and with or without type 2 diabetes mellitus were examined. The levels of P-selectin, Galectin-3 and hs-CRP were assessed in all patients. Results and discussion. The level of plasma Galectin-3 was 12.2±5.5 ng/ml, P-Selectin 90.0±46.5 ng/ml and hs-CRP 6.2±4.2 mg/l in the group of examined patients with verified stable angina. No correlation was found between the plasma levels of P-Selectin and hs-CRP in the examined patients (r= -0.131, p=0.284).The levels of P-Selectin and Galectin-3 in patients with stable angina were interrelated, but vary significantly at the individual level, which created the prerequisites for personalization of therapeutic goals for reducing the systemic inflammatory response. In patients with CABG, the level of P-Selectin was significantly higher (127.9±23.5, p<0.05). In the group of patients with IHD who received aspirin therapy at a dose of 75 mg/s, the level of P-Selectin did not differ significantly compared to patients who did not receive antiplatelet therapy. There was a decrease in the level of Galectin-3 in patients who received aspirin monotherapy, but this trend did not reach the level of reliability. In patients treated with clopidogrel at a dose of 75 mg, the P-Selectin level was significantly lower in comparison with patients who did not receive antiplatelet drugs and patients receiving monotherapy with aspirin (66.4±25.6 ng/ml, 97.2±19.3 ng/ml and 81.5±29.1 ng/ml, respectively, p<0.05). In patients who received DAT, the level of P-Selectin (57.9±28.1 ng/ml) was significantly lower than in patients who did not receive antiplatelet drugs and received aspirin monotherapy. In the group of patients with angina who received anticoagulant therapy, the P-Selectin level was significantly lower than in patients who did not receive anticoagulant therapy (73.1±21.1 ng/ml and 95.6±22.3 ng/ml, respectively, p<0.05). Conclusions. Clopidogrel therapy, in contrast to aspirin, leads to a decrease in the level of P-Selectin, which reflects a decrease in the activity of the platelet component of the systemic inflammatory response in atherosclerosis. The use of RAS blockers is also accompanied by a decrease in the systemic inflammatory response.

Keywords: angina pectoris, systemic inflammation, biomarkers, P-Selectin, Galectin-3, clopidogrel

Full text: PDF (Rus) 203K

  1. ESC 2013 guidelines on the management of stable coronary artery disease. European Heart Journal. 2013; 34: 2949-3003.
  2. Atlas Writing Group, Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2018 Feb 14;39 (7): 508-79.
  3. Gross PL. Soluble P-selectin is the smoke, not the fire. Blood. 2017 Jul 13; 130 (2): 101-2.
  4. Meyer A, Weithaeuser A, Steffens D, Bobbert P, Hassanein A, Ayral Y, Schultheiss HP, Rauch U. Inhibition of platelet function with clopidogrel is associated with a reduction of inflammation in patients with peripheral artery disease. Cardiovasc Revasc Med. 2016 Apr-May; 17 (3): 169-75.
  5. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016 Jan 8; 118 (1): 145-56.
  6. Ridker PM. How Common Is Residual Inflammatory Risk? Circ Res. 2017 Feb 17; 120 (4): 617-9.
  7. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21; 377 (12): 1119-31.
  8. Standards of Medical Care in Diabetes - 2017. Summary of Revisions: Diabetes Care. 2017 Jan; 40 (Supplement 1): S4-S5.
  9. Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018 Jan 1; 8 (3): 593-609.
  10. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013 Jan 11; 339 (6116): 161-6.
  11. Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013 May 21; 61 (20): 2048-55.